Wells Fargo Initiates Coverage On Design Therapeutics with Overweight Rating, Announces Price Target of $26

Benzinga · 2d ago
Wells Fargo analyst Tianqi Hang initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Overweight rating and announces Price Target of $26.